JBMR Plus, 2019 Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture.
Takahiro Mori +2 more
doaj +1 more source
The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication. [PDF]
, 2016 PurposeTo explore whether privacy restrictions developed to protect patients have complicated research within a 15-year surveillance study conducted with US cancer registries.MethodsData from enrolling 27 cancer registries over a 10-year period were ...
Andrews, Elizabeth B +6 more
core +1 more source
Acta Orthopaedica, 2018 Background and purpose — Teriparatide accelerates fracture healing in animals and probably in man. Abaloparatide is a new drug with similar although not identical effects on the teriparatide receptor.
Magnus Bernhardsson, Per Aspenberg
doaj +1 more source
More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery [PDF]
Asian Spine Journal, 2015 Study DesignRetrospective case series.PurposeTo examine the most effective duration of teriparatide use for spinal fusion in women with postmenopausal osteoporosis.Overview of LiteratureWe reported that daily subcutaneous injection of teriparatide ...
Seiji Ohtori +19 more
doaj +1 more source
Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment [PDF]
, 2014 The aim of this study was to evaluate the effect of strontium ranelate (SrR) on bone mineral density (BMD) and boneturnover markers after 1 year of treatment.
Brance, María Lorena +13 more
core +1 more source
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide [PDF]
, 2010 Summary We report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment.
A. Blumsohn +49 more
core +3 more sources
Teriparatide Induced Delayed Persistent Hypercalcemia
Case Reports in Endocrinology, 2014 Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually
Nirosshan Thiruchelvam +3 more
doaj +1 more source
Bisphosphonate's and Intermittent Parathyroid Hormone's Effect on Human Spinal Fusion: A Systematic Review of the Literature. [PDF]
, 2017 There has been a conscious effort to address osteoporosis in the aging population. As bisphosphonate and intermittent parathyroid hormone (PTH) therapy become more widely prescribed to treat osteoporosis, it is important to understand their effects on ...
Acosta, Frank L +9 more
core +2 more sources
Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. [PDF]
, 2020 The surgeon general of the USA defines osteoporosis as "a skeletal disorder characterized by compromised bone strength, predisposing to an increased risk of fracture." Measuring bone strength, Biomechanical Computed Tomography analysis (BCT), namely ...
Bouxsein, ML +6 more
core
Structure model index does not measure rods and plates in trabecular bone [PDF]
, 2015 Structure model index (SMI) is widely used to measure rods and plates in trabecular bone. It exploits the change in surface curvature that occurs as a structure varies from spherical (SMI = 4), to cylindrical (SMI = 3) to planar (SMI = 0).
Altman +61 more
core +3 more sources